RESEARCH ARTICLE

Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group

Elisa Fernandez-Cooke1*, Ana Barrios Tascoń2, Judith Sánchez-Manubens3,4, Jordi Antón5, Carlos Daniel Grasa Lozano1, Javier Aracil Santos6, Enrique Villalobos Pinto6, Daniel Clemente Garulo6, Beatriz Mercader Rodríguez7, Matilde Bustillo Alonso8, Esmeralda Núñez Cuadros8, María Luisa Navarro Gómez9, Sara Domínguez-Rodríguez11, Cristina Calvo5, on behalf of the KAWA-RACE study group

1 Department of Pediatrics, Hospital Universitario Doce de Octubre, Madrid, Spain, 2 Department of Pediatrics, Hospital Universitario Infanta Sofia, Madrid, Spain, 3 Department of Pediatric Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, 4 Department of Pediatric Rheumatology, Hospital Parc Taulí, Sabadell, Spain, 5 Department of Pediatrics, Hospital Universitario La Paz, Madrid, Spain, 6 Department of Pediatrics, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, 7 Department of Pediatrics, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 8 Department of Pediatrics, Hospital Universitario Miguel Servet, Zaragoza, Spain, 9 Department of Pediatrics, Hospital Regional Universitario de Málaga, Andalucía, Spain, 10 Department of Pediatrics, Hospital Universitario Gregorio Marañon, Madrid, Spain, 11 Fundación de Investigación Hospital 12 Octubre (Madrid, Spain), Fondazione PENTA ONLUS, Padova, Italy

¶ Membership of the KAWA-RACE study group is provided in the Acknowledgments.

* elisafcooke@gmail.com

Abstract

Background
Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology affecting mainly children less than 5 years of age. Risk factors for cardiac involvement and resistance to treatment are insufficiently studied in non-Japanese children.

Objective
This study aimed to investigate the epidemiology, clinical features and risk factors for resistance to treatment and coronary artery lesions (CAL) in KD in Spain.

Methods
Retrospective study (May 2011-June 2016) of all patients less than 16 years of age diagnosed with KD included in KAWA-RACE network (84 Spanish hospitals).

Results
A total of 625 cases were analyzed, 63% were males, 79% under 5 year-olds and 16.8% younger than 12 months. On echocardiographic examination CAL were the most frequent findings (23%) being ectasia the most common (12%). Coronary aneurysms were
diagnosed in 9.6%, reaching 20% in infants under 12 months (p<0.001). A total of 97% of the patients received intravenous immunoglobulin (IVIG) with a median number of days from fever onset to IVIG administration of 7.2. A second dose was given to 15.7% and steroids to 14.5% patients. Only 1.4% patients received infliximab. No deaths were reported. A multivariate analysis identified anemia, hypoalbuminemia, hyponatremia, higher creatinine and procalcitonin as independent risk factors for treatment failure and length under 103 cm, hemoglobin < 10.2 mg/dL, platelets > 900,000 cells/mm³, maximum temperature < 39.5˚C, total duration of fever > 10 days and fever before treatment ≥ 8 days as independent risk factors for developing coronary aneurysms.

Conclusions
In our population, children under 12 months develop coronary aneurysms more frequently and children with KD with anemia and leukocytosis have high risk of cardiac involvement. Adding steroids early should be considered in those patients, especially if the treatment is not started before 8 days of fever. A score applicable to non-Japanese children able to predict the risk of aneurysm development and IVIG resistance is necessary.

Introduction
Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology presenting predominantly in children less than 5 years of age. Diagnosis is based on clinical criteria that include fever, exanthema, conjunctivitis, changes in the extremities, erythema of oral mucosa and lips and cervical lymphadenopathy. The prognosis depends mainly on the extent of cardiac involvement that can be minimized if treatment with intravenous immunoglobulin (IVIG) is administered before the 10th day of disease[1,2].

The etiology of KD is still unknown, although clinical, laboratory and epidemiological features suggest an infectious origin or trigger. However, many studies have failed to identify a unique etiological infectious agent and studies on other biomarkers have tried to recognize the disease early[3,4]. On the other hand, activation of the immune system is characteristic of KD and genomewide association studies have identified a number of plausible loci involved in KD [5–8]. To date, KD diagnosis is still mainly based on clinical criteria although a recent study has described a 13-transcript blood gene expression signature that distinguished KD from other febrile conditions[9].

KD has a universal distribution but is more prevalent in Asian countries, especially in Japan, with an increasing annual incidence of 308 per 100,000 children <5 years in 2014[10]. In Europe incidences range between 4.9 and 15.2 per 100,000 children <5 years of age[11,12]. In Spain, the first population-based study on the epidemiology of KD was published by the KD Catalonian Working Group reporting a mean annual incidence in Catalonia of 3.5/100,000 children <14 years old and 8/100,000 children <5 years (2004–2013)[13]. More recently an incidence of 11.7/100,000 children <5 years has been reported (2005–2015) for the whole of Spain, but this study was a retrospective ecological study and may be overestimating the real incidence [14,15]. Surveillance KD studies are important to monitor trends and outcomes of the disease.

In 2015 a KD study group named KAWA-RACE was set up aiming to investigate the epidemiology, clinical features, risk factors for coronary artery lesions (CAL), specially coronary aneurysms, management and outcome of KD in Spain.
Materials and methods

Network setup: During 2015 a call for pediatricians who work with KD patients was sent out through the national societies of infectious diseases, rheumatology and cardiology to set up a KD study group that was named KAWA-RACE. A total of 187 pediatricians from 84 Spanish hospitals joined the network. The ethics committee at Instituto de Investigación Hospital 12 de Octubre approved this study (CEIC 15/316). All patient data were fully anonymized before we accessed them.

Data source and collection: We identified all children who were discharged from these hospitals with an International Classification of Diseases (ICD) coding for KD (ICD9 446.1). Retrospective medical data retrieval from 5 years (May 2011–June 2016) was collected and reviewed. A research electronic database capture [16] was created and sent to the participant clinicians together with the study protocol. The patient’s demographic, clinical, laboratory and echocardiographic data were recorded. Egami[17], Sano[18] and Kobayashi[19] scores were calculated.

Subjects and Case Definitions: Individual patient data were reviewed to confirm the diagnosis of KD according to the American Academy of Pediatrics and the American Heart Association (AHA) in 2004[20], including coronary aneurysms criteria. Diagnosis of incomplete KD was made in cases with fewer classical diagnostic criteria and with several compatible clinical, laboratory, or echocardiographic findings, excluding those of other febrile illnesses according to AHA. All patients less than 16 years of age diagnosed with KD diagnosis were included in the study. Exclusion criteria were: Patients older than 16 years at the time of diagnosis, those patients found to be duplicated in the database and patients with a final alternative diagnosis.

Resistance to treatment was defined as persistence of fever 36 hours after the end of IVIG infusion. Minimum follow up was considered 6 months.

Statistical Analysis: Baseline characteristics were described through summary tables reporting frequencies and total records in case of categorical variables and mean (standard deviation) or median (interquartile range (IQR)) when continuous. Chi-squared and Fisher-test (low cell sizes < 20) were applied to assess differences among groups for categorical variables. For continuous variables Student T-test and U-Mann-Whitney were applied in parametric and non-parametric distributions respectively. Normality was tested by means of Shapiro-Wilk test. Optimal cutpoint for continuous variables were assessed by means of the maximum AUC values predicting aneurism including 100 bootstrapped samples implemented in cutpoint package[21]. In order to estimate the effect of the different sociodemographic and clinical characteristics with the primary outcomes odds ratios (ORs) were calculated by means of normal and multivariable logistic regression adjusting for age at hospitalization. To test possible non-linear associations with the risk of developing aneurisms, a generalized additive logistic model was performed, and the probability risk of developing aneurism was plotted either for univariate or multivariate analysis. Smoothing parameters defining degrees of freedom (df) were selected according to nested AIC comparisons. Plots were built with ggplot2 and itsadugR packages. R software was used for all analysis[22].

Results

Epidemiology

Nationwide, 654 cases were collected, 29 cases were excluded for not meeting inclusion criteria. Thus, 625 cases were included for analysis. Sixty-three percent were males giving a gender ratio of 1.58:1 and age at diagnosis ranged from 49 days to 15.6 years (median: 2.8 years). Over
all 494 (79%) cases occurred in children under 5 years. Forty-two cases (6.7%) were younger than 6 months and 103 cases (16.5%) younger than 12 months. The patients were mainly of European origin (76%) followed by Central and South America (6%) and Asia (5%). A total of 441 were classified as complete (70.5%) and 184 as incomplete (29.5%) KD. Amongst patients younger than 6 and 12 months the proportion of incomplete cases was significantly higher than the group older than 6 and 12 months (52% vs 28%, \( p < 0.001 \)) and (25% vs 14%, \( p < 0.001 \)), respectively. In 13 (2%) cases it was not the first episode of KD. The onset of KD was more common in winter (28%) and spring (28%), whereas it was relatively less frequent in autumn (19%). Fig 1 represents age (A) and seasonal distribution (B).

Data on family history for first and second degree relatives was available for 560/625 patients and only 5 (0.9%) patients reported relatives with previous KD; in 2 cases it was the mother; in 2 cases, a cousin and in 1 case, a sibling.

**Clinical characteristics**

Clinical data of the patients are shown in Table 1. The most common manifestation was fever persisting for 5 days or longer (99.5%) followed by lips and oral changes in both complete and incomplete forms. Only 8% reported that fever was preceded by another symptom. We compared the data between complete and incomplete KD (Table 1) and changes in extremities and acute lymphadenopathy were the least common classical diagnostic criteria present in incomplete cases. Desquamating rash on the groin was significantly less frequent in incomplete KD (17% vs 12%, \( p = 0.008 \)).

Despite diagnosing and treating for KD, clinicians suspected a different entity in 21% of cases, mainly scarlet fever followed by viral infections. A positive microbiological finding was found in 101 (16%) patients, and they were mainly respiratory viruses (35 cases) and pharyngeal *Streptococcus* group A (29 cases).

On laboratory findings, children with incomplete KD had significantly lower hemoglobin levels (median value 10.6g/L vs 11.0 g/L, \( p < 0.001 \)) and higher white cell count (median value 19,500×10⁹/L vs 15,850×10⁹/L, \( p < 0.001 \)) (Table 2). The overall terminal segment of the natriuretic atrial peptide (NT-proBNP) before treatment was (median IQR; 394 (180–1034) pg / ml.

**Heart lesions**

Electrocardiographic studies during admission revealed alterations in 47/608 (7.7%) patients, mainly of low voltage in 18 cases, and followed by repolarization alterations in 11 cases.

---

**Fig 1.** Age (A) and seasonal (B) distribution of Kawasaki disease patients in Spain, from 2011 through 2016.

[https://doi.org/10.1371/journal.pone.0215665.g001](https://doi.org/10.1371/journal.pone.0215665.g001)
Echocardiographic examinations were performed during the acute phase of KD in 99% of the cases, among which 32% were found to have an abnormal echocardiogram. CAL were the most frequent findings in 144 patients (23% of cases). Of these, ectasia was the most common lesion, diagnosed in 75/621 patients (12% of cases). Coronary aneurysms were diagnosed overall in 60/621 patients (9.6%) and in 21/103 (20%) infants under 12 months ($p<0.001$). Twenty-eight aneurysms persisted more than 6–8 weeks (4.5% of the total patients). Five cases were diagnosed with giant aneurysms (0.8%). Other data are shown in Table 3. Only 127/621 patients underwent tests looking for peripheral aneurysms and of these 26 (20%) were diagnosed of a peripheral aneurysm, mainly by doppler ultrasound.

**Treatment and outcome**

Treatment with IVIG was given to 97% of the patients (606 cases). The median number of days since the first day of fever to IVIG administration was 7.2 (range 0–67) and overall 85% of the children (83% with incomplete and 86% with complete KD) received IVIG within the first 10 days from the onset of the disease. Only 9.5% of patients reported side effects, mainly...
fever recrudescence during infusion (8 cases; 1.3%) and neck stiffness (6 cases; 1%). The majority of patients received acetyl salicylic acid (543/625, 87%). Among the patients treated with IVIG, 15.7% (98 cases) did not respond and received a second dose and 1.6% (10 cases) required a further dose. Steroids were given to 91 (14.5%) patients, 18 of whom (20%) received them as initial therapy together with IVIG. A higher, non-significant proportion of patients that received steroids were <6 months (23.8% vs 13.8%, p = 0.124). Only 9 (1.4%) patients received other immunosuppressive therapies, infliximab in all of them. Blood transfusions for anemia were required in 4 (0.6%) patients. Only one case of neurosensory hearing loss was described. Out of the 30 (5%) patients admitted to the pediatric intensive care unit, a significantly higher proportion of them were younger than 6 months (18% vs 4%, p = 0.002). The main cause of admission was suspicion of sepsis (37%) and myocardial dysfunction (17%). Permanent sequelae were reported in 27 (4.3%) patients, mainly due to permanent CAL (giant aneurisms in 2 cases; 7% of patients with sequelae); one patient had myocardial dysfunction,

| Variable          | Median [IQR] n/N Complete KD [N = 441 (70.5%)] | Incomplete KD [N = 184 (29.4%)] | p-value |
|-------------------|-----------------------------------------------|---------------------------------|---------|
| Hemoglobin g/dl (min) | 11.00 [10.2–11.9] (n = 432) | 10.6 [9.8–11.6] (n = 180) | <0.001 |
| White cell count x10^9/L (max) | 15,815 [12,650–20,477] (n = 350) | 19,500 [14,950–22,700] (n = 135) | <0.001 |
| Platelets x10^12/L (min) | 327,000 [252,500–402,000] (n = 423) | 335,500 [255,250–414,500] (n = 180) | 0.883 |
| Platelets x10^12/L (max) | 574,000 [453,500–731,000] (n = 423) | 600,500 [458,000–805,500] (n = 180) | 0.254 |
| ESR mm/h | 72.0 [48.0–102.7] (n = 350) | 75.0 [43.7–104.7] (n = 140) | 0.791 |
| CRP mg/l | 15.0 [6.9–32.3] (n = 430) | 13.2 [7.1–23.3] (n = 180) | 0.267 |
| Albumin g/L | 3.1 [2.7–3.6] (n = 334) | 3.2 [2.6–3.8] (n = 146) | 0.913 |
| ALT IU/L | 45.5 [20.0–100.2] (n = 400) | 35.0 [20.0–86.5] (n = 170) | 0.473 |
| NT-proBNP pg/ml | 460.5 [200.2–1336.5] (n = 68) | 444.0 [228.0–986.5] (n = 18) | 0.983 |

IQR: interquartile range, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, ALT: Alanine transaminase, NT-proBNP: N-terminal pro b-type natriuretic peptide

https://doi.org/10.1371/journal.pone.0215665.t002

Table 3. Cardiological findings in children with Kawasaki disease.

| Finding                              | Total patients = 625 |
|--------------------------------------|----------------------|
| Coronary artery lesions              | 144 patients (23%)   |
| Ectasia                              | 75 patients (12%)    |
| Coronary aneurysms                   | 60 patients (9.6%)   |
| Number of aneurysms (mean, range)    | 1.82 (1–6)          |
| Diameter of aneurysms (mean, range)  | 4.2 (2.1–12) mm     |
| Giant aneurysms (cases)              | 5 (0.8%)             |
| Number of affected vessels (mean, range) | 1.8 (1–4)    |
| Coronary affected                    | Left main coronary artery (23/60; 38%) |
|                                     | Right coronary artery (19/60; 31%) |
|                                     | Left anterior descending artery (13/60; 21%) |
|                                     | Left circumflex coronary artery (6/60; 10%) |
| Persistence aneurysms (> 6–8 weeks)  | 28 (4.5%)            |
| Valvular involvement                 | 57 patients (9.2%)   |
| Pericardial effusion                 | 48 patients (7.7%)   |
| Transient left ventricular systolic dysfunction | 7 patients (1.1%) |

https://doi.org/10.1371/journal.pone.0215665.t003
another complete atrioventricular heart block and a third hemophagocytic lymphohistiocytosis. No deaths were reported.

**Risk factors for resistance to treatment**
A total of 98 (15.7%) children had IVIG resistance and needed a second dose. A univariate analysis was performed to identify the possible risk factors for resistance to treatment (Table 4). Non-responder patients had a higher proportion of aneurysms (15% vs 8%), lower hemoglobin, albumin and sodium in serum and higher maximum platelet and leucocyte count, higher creatinine, and procalcitonin in serum. The clinical data were similar between responders and non-responders except for the presence of rash that was more frequent in those who had resistance to treatment. When a multivariate analysis was performed, anemia, hypoalbuminemia, hyponatremia and higher creatinine and procalcitonin were independent risk factors for non-response to the initial IVIG (Table 4). Although fever until treatment > 8 days was associated with non-response, it did not remain significant in the multivariate analysis and neither did the Kobayasi score.

When risk scores of non-response to the initial IVIG were analyzed, children that needed a second dose of IVIG had more frequently a Kobayasi score ≥ 5. No differences were found in the mean Egami and Sano scores between responders and no responders. The sensitivity and specificity of the scores are detailed in Table 5.

**Risk factors for developing coronary aneurysms**
A total of 60 children (9.6%) developed coronary aneurysms. A univariate analysis was also performed to identify risk factors for developing coronary aneurysms (Table 6). Children with

| Table 4. Risk factors for resistance to treatment with IVIG. Univariate and multivariate analysis. |
|-----------------------------------------------|
| **Univariate Analysis OR [95% CIs]** | p-value | **Multivariate Analysis† OR [95% CIs]** | p-value |
|-----------------------------------------------|-----------------|-----------------------------------------------|------------------|
| **Age at hospitalization (y)** | 1.5 [0.85;2.5] | 0.151 | - | - |
| **Hemoglobin (g/dl)** | 2.5 [1.61;3.94] | < 0.001 | 2.5 [1.54;4.12] | < 0.001 |
| <10.2 | - | - | - | - |
| **Sodium (meq/L)** | 3.5 [2.54;6.45] | < 0.001 | 2.9 [1.7;5.4] | < 0.001 |
| <136 | - | - | - | - |
| **Creatinine (mg/dl)** | 2.5 [1.5;4.2] | < 0.001 | 3.2 [1.8;5.9] | < 0.001 |
| ≥0.4 | - | - | - | - |
| **Albumin (g/L)** | 2.9 [1.7;5.1] | < 0.001 | 3.1 [1.8;5.6] | < 0.001 |
| <3.3 | - | - | - | - |
| **Procalcitonin (ng/mL)** | 5.5 [2.1;14.0] | 0.001 | 9.4 [3.3;27.9] | < 0.001 |
| ≥5.5 | - | - | - | - |
| **Aneurysm** | 1.95 [1.00;3.59] | 0.049 | 2.3 [1.1;4.4] | 0.002 |
| Yes | - | - | - | - |
| **Fever duration until treatment (d)** | 3.0 [1.7;5.4] | 0.001 | 0.7 [0.42;1.2] | 0.251 |
| ≥8 | - | - | - | - |
| **Kobayashi** | 1.9 [1.1;3.38] | 0.031 | 1.5 [0.78;2.9] | 0.204 |
| ≥5 points | - | - | - | - |
| **Echocardiogram alterations** | 2.2 [1.44;3.48] | < 0.001 | 1.9 [1.1;3.0] | 0.012 |
| Yes | - | - | - | - |
| * Adjusted by Age at hospitalization. |

https://doi.org/10.1371/journal.pone.0215665.t004
coronary aneurysms were younger (mean of 23 vs 34 months), weighed less than 14 kg and had a height under 103 cm more frequently. The group between 6 and 12 months developed aneurysms in a significantly high proportion of cases, up to 23%. Males developed aneurysms more frequently. A higher proportion of children that developed aneurisms had duration of fever for longer than 10 days and oral lesions were less common. Hypotension and shock were also more frequent in children without coronary aneurysms. Regarding blood analysis, anemia; higher value of maximum platelets and leucocytes were present in children with aneurisms.

None of the analyzed scores (Egami, Sano or Kobayashi), nor the type of KD (complete or incomplete) were associated with higher risk of aneurysms. Children who suffered from a pre-vious infection or those with a microbiological identification presented the same proportion of aneurysms. Patients with aneurysms more frequently received steroids and infliximab.

When a multivariated analysis was performed we found that independent risk factors for developing coronary aneurysms were, length under 103 cm; OR = 4.9 [CI 95%: 1.3–31.7], hemoglobin < 10.2 mg/dL; OR = 2.2 [CI 95%: 1.2–4.1], platelets > 900,000 cells/mm³; OR = 3.3 [CI 95%: 1.54;6.99], maximum temperature < 39.5°C; OR = 2.8 [CI 95%: 1.1–9.70], duration of fever > 10 days; OR = 4.8 [CI 95%: 2.54–9.11] and fever before treatment ≥ 8 days OR: 3.9 [CI 95%; 2.1;7.5] (Fig 2).

According to the generalized additive logistic model, age at hospitalization (df = 4), hemoglobin (df = 5), platelets (df = 6), maximum temperature (df = 5) and leukocytes presented a
non-linear association with the probability risk of developing aneurism. Interestingly, days of fever until IVIG treatment (df = 7) presented a concave curve effect in the multivariate and a bimodal for the univariate. The probability of developing aneurisms was higher in younger age at hospitalization (0–4 years), reaching a plateau effect from 8 years of age. A similar association was found for hemoglobin and maximum temperature, when hemoglobin and temperature increase, the probability of aneurisms decreases exponentially until they reach values of 10g/dl and 40˚C respectively of plateau effect. Higher levels of platelets and leukocytes increase the risk of developing aneurisms. These effects were more pronounced after 1,000,000 platelets/mm$^3$ and 30,000 leukocytes/mm$^3$ (Fig 3).

**Discussion**

This is the first national multicenter epidemiological and clinical study on KD in Spain. From a total of 625 children with KD, coronary aneurysms were detected in 60 cases (9.6%), and we identified as primary risk factors associated with their development, the presence of anemia; child’s height bellow than 103 cm, maximum platelets greater than 900,000 / mm3, the total duration of fever greater than 10 days and the duration of fever > 8 days before treatment. In our series, resistance to IVIG treatment was found in more than 15% of the cases, with the development of aneurysms being more frequent in those cases. The known predictive scores of treatment failure are not applicable in our population as it has been described in other non-Japanese populations[23,24].

---

**Table 6. Risk factors for developing aneurysms.** Univariate and multivariate analysis.

|                              | Univariate Analysis OR [95% CIs] | p-value | Multivariate Analysis* OR [95% CIs] | p-value |
|------------------------------|---------------------------------|---------|-------------------------------------|---------|
| Age at hospitalization (y)   |                                 |         |                                     |         |
| ≤1                           | 3.4 [1.97; 6.64]                | 0.002   | -                                   | -       |
| Gender                       |                                 |         |                                     |         |
| Male                         | 2.4 [1.2;5.03]                 | <0.001  | -                                   | -       |
| Weight (kg)                  |                                 |         |                                     |         |
| ≤ 14                         | 3.1 [1.57;0]                   | 0.001   | 2.2 [0.85;6.1]                      | 0.111   |
| Length (cm)                  |                                 |         |                                     |         |
| ≤ 103                        | 5.3 [1.87;0]                   | 0.001   | 4.9 [1.3;31.7]                      | 0.038   |
| BMI                          |                                 |         |                                     |         |
| > 18.3                       | 0.7 [0.22;0]                  | 0.112   | 0.4 [0.1;1.44]                      | 0.230   |
| Hemoglobin (g/dl)            |                                 |         |                                     |         |
| ≤ 10.2                       | 2.4 [1.10;4.42]                | <0.001  | 2.2 [1.2;4.1]                      | 0.012   |
| Platelets (cell/mm$^3$)      |                                 |         |                                     |         |
| > 900,000                    | 4.6 [2.4;8.51]                | <0.001  | 3.3 [1.5;4.699]                     | 0.002   |
| Leukocytes (cell/mm$^3$)     |                                 |         |                                     |         |
| > 16,800                     | 2.2 [1.1;8.10]                | <0.001  | 1.5 [0.66;3.53]                     | 0.341   |
| Maximum Temperature (˚C)     |                                 |         |                                     |         |
| ≤ 39.5                       | 2.7 [1.15;8.15]               | <0.001  | 2.8 [1.1;9.70]                      | 0.006   |
| Total fever duration (d) from the beginning of symptoms | | | | |
| > 10                         | 3.6 [2.06;3]                  | <0.001  | 4.8 [2.6;9.3]                      | <0.001  |
| Fever duration before treatment (d) | | | | |
| ≥ 8                          | 3.0 [1.7;5.4]                 | <0.001  | 3.9 [2.1;7.5]                      | <0.001  |

* Adjusted by age at hospitalization and gender.

https://doi.org/10.1371/journal.pone.0215665.1006
The epidemiology of our patients is similar to that described in other countries around us. Gender and age distribution were similar to most reports, boys were more commonly affected and most of the cases occurred in children <5 years with incidence peaking in children 1 year of age [1,13,25]. The male/female reported ratio is approximately 1.5 to 1 and is consistent with
our findings [26]. The most commonly affected race was of European origin representing the main population in our country. The seasonal distribution of incidence rates were maximum during winter and spring as reported in European and most Asian studies [27,28] and differing from some Asian studies that report greater incidence during summer [25].

The clinical manifestations of KD in Spain were very similar to those shown in other studies [13,25,29]. The rate for incomplete forms of KD in our study (29.6%) was within the range of those reported in the literature but lower than the rate described in a Spanish study performed in the region of Catalonia (39.8%) possibly indicating increased awareness of KD in this region [13]. Fever persisting for 5 days or longer was still the most frequent clinical manifestation of KD, followed by changes of lips and the least frequent symptom was acute non-purulent cervical lymphadenopathy [30].

Children with KD typically have leukocytosis. Many children have a normocytic normochromic anemia and platelet counts are usually elevated by the end of the first week of illness with counts exceeding 1 million/mm$^3$ in some cases. Inflammatory markers are elevated in nearly all patients with KD. Measurements of the erythrocyte sedimentation rate (ESR) are helpful in assessing the degree of inflammation at diagnosis and before IVIG administration. The analytical values of our patients were also similar to those previously described [30]. In our series, the presence of anemia, hypoalbuminemia, hyponatremia and elevation of procalcitonin were risk factors for non-response to treatment and anemia was also an independent risk factor for development of aneurysms. Chen et al, also found anemia as a risk factor for the development of CAL but did not specify if this also applies to aneurysms alone [25]. Recently, hepcidin has been described as inducing transient hyposideremia, anemia, and hypothesized to influence disease outcomes in KD [31].

The percentage of coronary dilation (ectasia) in our series was lower (12%) than in other series that describe an incidence of up to 30% of children by Z-score criteria (Z>2), even when treated with high-dose IVIG regimens within the first 10 days of illness [1]. The percentage of coronary aneurysms (9.6%) and giant aneurysms (0.8%) in our cohort is high when compared to Asian series (Japan (1.05 and 0.91%), Korea (1.7 and 0.16%), and Shanghai (1.1 and 0.7%) but smaller than those published in USA (13%) [33], The Netherlands (13.5%) [26], Germany (17%) [28] or United Kingdom (19%) [34] and approximate to those described in series of neighboring countries such as Portugal (8.5%) [35]. This discrepancy may be due to different classification systems and should be interpreted with caution. Mitral regurgitation and pericardial effusion are more frequent in our cases (6.7%, 7.7%) but mild and transient as in other series [29,35]. The disparity in the rate of coronary involvement when compared to Asian series could be related to genetic conditions or to delayed diagnosis of the disease in European countries due to its lower incidence. In Asian countries they treat children earlier than in Europe, on the third or fourth day, due to a high index of suspicion, which can also condition a better prognosis. Compared with the countries in our geographical region, our percentage of aneurysms is low, and could rely on the presence of pediatricians in primary care settings and awareness of the disease. Children with coronary aneurysms received IVIG later than those without (median 10 days vs 7 days) in a study from the UK [34]. In our series, treatment after 8 days was an independent risk factor despite the timing from the first symptom to diagnosis being less than 10 days in 85% of our children.

The efficacy of IVIG administered in the acute phase of KD is well established to reduce the prevalence of CAL with higher doses given in a single infusion having the greatest efficacy [1,36]. In our study treatment with IVIG was given to 97% of the patients, in spite of which, we have a 15% of patients with resistance to treatment, being in these cases more likely the development of aneurysms. This proportion is higher than the 4.9% rate reported by Chen et al [25] but within the range of 10% to 20% described in the recent American Heart Association.
statement by McCrindle et al in 2017[1]. Steroids were given to 15% of the children in our study; and only a small proportion initially together with IVIG, reflecting that they are used mostly in patients who have a poor response to the initial dose of IVIG. Results from the RAISE (Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease) study showed that addition of prednisolone to the standard regimen of IVIG improves coronary artery outcomes in patients with severe KD in Japan[37]. Moreover, a recent Cochrane review concludes that the evidence suggests that treatment with a long course of steroids should be considered for all children diagnosed with KD [38] although there are authors calling to take this with caution in unselected non-Japanese populations as two US trials included in the meta-analysis did not demonstrate significant benefit from primary adjunctive steroids[39]. Therefore, we need to identify patients with high risk of failure to treatment and development of aneurysms in order to achieve an earlier and effective treatment as the validated scores in Asian population (Egami, Sano and Kobayashi) were not of utility in our population. In our series, the development of aneurysms was independently associated with a smaller height of the patients (probably indirectly with age), with anemia < 10.2 gr/dL, with leukocytosis greater than 16,000 cell/mm$^3$ and with a treatment delay of more than 8 days. Therefore, when these factors are present, adding steroids to the initial treatment should be considered. Age is considered a risk factor (< 12 months of age), and our results confirmed this, constituting the group of patients that develop aneurysms in a higher proportion. Indeed, we consider that in children younger than 1 year of age, we should be very cautious and consider beginning treatment with steroids together with IVIG, as many authors are recommending. For the same reason, some authors recommend performing an echocardiogram on infants with fever without a source for 7 days or longer with elevated inflammatory markers[1,25]

Our study has several limitations. One of them is that we could not calculate an overall incidence of KD as our network did not achieve total national coverage. The retrospective character of our study is also a main limitation, because of missing data in some parameters. Also, further tests looking for distal lesions in the coronary arteries were made in very few patients so there is a potential underestimation of persistent CAL. Nevertheless, we think that the number of patients collected allow us to draw some conclusions in terms of risk factors, that could be validated in a prospective study already ongoing in the KAWA-RACE group.

More studies are necessary in our population and it would be of interest to validate a score for non-Japanese children to be able to predict the risk of aneurysm development and treatment failure that would allow for selecting patients that would benefit from early steroids or other immunosuppressive treatments. Meanwhile, we recommend being extremely cautious with children under 12 months, with anemia and leukocytosis and to consider adding steroids early in those patients, especially if the treatment is not started before 8 days of fever.

**Supporting information**

S1 File. KAWA-RACE data set.
(XLSX)

S2 File. KAWA-RACE code book for data set interpretation.
(PDF)

**Acknowledgments**

We also would like to thank the different Spanish medical pediatric societies that have made the KAWA-RACE network possible; SEIP, SERPE and SECPCC.
We thank the KAWA-RACE study group for taking part in this study and contributing by data entering their patients.

**The KAWA-RACE study group is composed by:**

**Study coordinator:** Elisa Fernández-Cooke (Hospital Doce de Octubre, Spain).

**Scientific committee:** Elisa Fernandez-Cooke (Hospital Doce de Octubre, Madrid), Cristina Calvo (Hospital Universitario La Paz, Madrid), Ana Barrios Tascón (Hospital Universitario Infanta Sofia, Madrid), Judith Sánchez-Manubens (Hospital Sant Joan de Deu, Barcelona), Jordi Antón (Hospital Sant Joan de Deu, Barcelona), Javier Arcil Santos (Hospital Universitario La Paz, Madrid), Esmeralda Nuñez Cuadros (Hospital Regional Universitario de Málaga), Maria Luisa Navarro Gómez (Hospital Universitario Gregorio Marañón, Madrid), David Moreno Pérez (Hospital Regional Universitario de Málaga).

**Collaborating members:**

María Martín Cantero (Hospital Regional Universitario de Málaga), Esmeralda Nuñez Cuadros (Hospital Regional Universitario de Málaga), Begona Carazo Gallego (Hospital Regional Universitario de Málaga), Leticia Isabel Martinez Campos (Hospital La Inmaculada, Almería), Fernando Sánchez García (Hospital La Inmaculada, Almería), Marisol Camacho Lovillo (Hospital Virgen del Rocío, Sevilla), Renata Marqués (Hospital Virgen del Rocío, Sevilla), Olaf Neth (Hospital Virgen del Rocío, Sevilla), Laura Fernández Silveira (Hospital Virgen del Rocío, Sevilla), Miguel Sánchez Forte (Hospital Torrecardenas, Almería), Ángeles Ortega Montes (Hospital Torrecardenas, Almería), Beatriz Bravo Manchón (Hospital Universitario Virgen de las Nieves, Granada), Margarita Camacho (Hospital Universitario Virgen de las Nieves, Granada), Antonio F Medina Claros (Hospital de la Axarquía, Murcia), Carlos Salido (Hospital de Jerez), Rafael Chulian Cruz (Hospital de Jerez), María Torres Rico (Hospital Juan Ramón Jiménez de Huelva), Mª Ángeles Tejero Hernández (Hospital Reina Sofia de Córdoba), Elena Gómez Guzmán (Hospital Reina Sofia de Córdoba), Mª José Arroyo Marín (Hospital Reina Sofia de Córdoba), José Rumbao Aguirre (Hospital Reina Sofia de Córdoba), Mª José Lirola Cruz (Instituto Hispalense de pediatría, Sevilla), Kety Maya Carrasco (Instituto Hispalense de pediatría, Sevilla), Moisés Rodríguez González (Hospital Universitario Puerta Del Mar de Cádiz), Enrique Blanca Jover (Complejo Hospitalario Granada), Aida Ruiz López (Complejo Hospitalario Granada), José Uberos Fernández (Complejo Hospitalario Granada), María Mercedes Ibáñez Alcalde (Hospital de Poniente, Almería), Pilar Collado (Hospital Universitario Miguel Servet, Zaragoza), Carmelo Guerrero Laleona (Hospital Universitario Miguel Servet, Zaragoza), Lorenzo Jiménez Montañés (Hospital Universitario Miguel Servet, Zaragoza), Ariadna Ayerza Casas (Hospital Clínico Universitario Lozano Blesa, Zaragoza), Bárbara Montes Zapico (Hospital San Agustín, Avilés), Carlos Pérez Méndez (Hospital San Agustín, Avilés), Javier Fernández Aracama (Hospital Universitario Basurto, Bilbao), Lucía Rodríguez (Hospital Central de Asturias, Oviedo), María Aleida Ibáñez Fernández (Hospital Central de Asturias, Oviedo), Sandra Navarro Campo (Hospital Central de Asturias, Oviedo), Silvia Escrivá Bori (Hospital Universitario Son Espases, Palma de Mallorca), María Concepción Mir Perelló (Hospital Universitario Son Espases, Palma de Mallorca), Mª Ángeles de la Fuente Sánchez (Hospital Universitario Son Espases, Palma de Mallorca), Patricia Aparicio García (Hospital Son Llátzer, Palma de Mallorca), Carlos Briales (Hospital Son Llátzer, Palma de Mallorca), Joaquín Castilla Crespi (Hospital Son Llátzer, Palma de Mallorca), María Elena Colino Gil (Hospital Materno-Infantil de Las Palmas de Gran Canaria), Nerea Delgado Cabrera (Hospital Materno-Infantil de Las Palmas de Gran Canaria), Ana Bello Naranjo (Hospital Materno-Infantil de Las Palmas de Gran Canaria), Jesús Poch Páez (Hospital Materno-Infantil de Las Palmas de Gran Canaria), Moneynia García Yáñez (Hospital Materno-Infantil de Las Palmas de Gran Canaria), Montse González García (Hospital Universitario Nuestra señora de Candelaria de Santa Cruz de Tenerife), Elena Pereira Bezanilla (Hospital Universitario...
Marqués de Valdecilla, Santander), Beatriz Jiménez Montero (Hospital Universitario Marqués de Valdecilla, Santander), Olga Domínguez García (Hospital Virgen de la Salud de Toledo), Begoña Losada Pinedo (Hospital Virgen de la Salud de Toledo), Gema Iñigo Martín (Hospital Virgen de la Salud de Toledo), Lucía María Escribano Gómez (Hospital General de Albacete), Antonio Cepillo (Hospital General de Albacete), Miguel Lillo Lillo (Hospital General de Albacete), María Isabel Buedo (Hospital General de Albacete), Laura del Rey (Hospital General de Albacete), Elena Urbezaneja Rodríguez (Hospital Clínico Universitario de Valladolid), Sara Rellán Rodríguez (Hospital Clínico Universitario de Valladolid), Teresa Cantero (Hospital de Palencia), Beatriz Plata Izquierdo (Complejo Asistencial Universitario de Salamanca), Luisa García-Cuenllas Álvarez (Complejo Asistencial Universitario de Salamanca), Ignacio Oulego Erroz (Hospital de León), Elena Pérez Santaolalla (Hospital Universitario de Burgos), Carlos Alcalde Martín (Hospital Universitario Río Hortega de Valladolid), Fernando Centeno Malfaz (Hospital Universitario Río Hortega de Valladolid), Elena Pérez Gutiérrez (Hospital Universitario Río Hortega de Valladolid), Marisol Jiménez Casso (Hospital General de Segovia), Fredy Prada (Hospital Sant Joan de Déu, Barcelona), Rosa Bou (Hospital Sant Joan de Déu, Barcelona), Estibaliz Iglesias (Hospital Sant Joan de Déu, Barcelona), Joan Calzada (Hospital Sant Joan de Déu, Barcelona), Olga Calavia Garsaball (Hospital Joan XXIII de Tarragona), Marc Tobeña Rue (Hospital Vall d’Hebron, Barcelona), Gemma Giralt García (Hospital Vall d’Hebron, Barcelona), Silvia Yevenes Ruiz (Hospital Vall d’Hebron, Barcelona), Zulema Lobato (Xarxa Assistencial i Universitaria de Manresa), Neus Rius Gordillo (Hospital Sant Joan de Reus), Montserrat Pasqual Torres (Hospital Sant Joan de Reus), María Méndez Hernández (Hospital Germans Trias i Pujol de Badalona), Lourdes García (Hospital de Mataró), Sergio Flores Villar (Hospital Universitario Mutua de Terrassa), Laura Minguell Domingo (Hospital Arnau de Vilanova, Lleida), Anna Ballester (Hospital de Calella), Ana Miralles (Hospital de Palamós), Berta Pujol Soler (Hospital General de Granollers), Anton Fougèt Vidal (Hospital General d’Olot), Pere Sala Castellví (Hospital de Barcelona), Angelita Serrano Aguilar (Hospital Comarcal Móra d’Ebre), José Manuel Siurana Rodríguez (Fundación Hospital de Nens de Barcelona), Anna Sangorrín Iranzo (Fundación Hospital de Nens de Barcelona), Roser Álvarez Pérez (Hospital de la Santa Creu i Sant Pau de Barcelona), Paula Rubes Cajas (Hospital General de Catalunya), Pere Genaro i Jornet (Hospital Verge de la Cinta, Tortosa), Ana Grande Tejada (Complejo Hospitalario Universitario Infanta Cristina, Badajoz), Cristina Zarallo (Complejo Hospitalario Universitario Infanta Cristina, Badajoz), Federico Martinón-Torres (Hospital Clínico Universitario de Santiago de Compostela), Irene Rivero Calle (Hospital Clínico Universitario de Santiago de Compostela), Antonio Justicia Grande (Hospital Clínico Universitario de Santiago de Compostela), Beatriz Ruiz Saez (Hospital Clínico Universitario de Santiago de Compostela), María López Sousa (Hospital Clínico Universitario de Santiago de Compostela), Alejandro Souto Vilas (Hospital Clínico Universitario de Santiago de Compostela), Bernardo López Abe (Hospital Clínico Universitario de Santiago de Compostela), Elisa de Miguel Esteban (Hospital San Pedro, Logroño), Bibiana Riaño Méndez (Hospital San Pedro, Logroño), Daniel Blázquez (Hospital Universitario Doce de Octubre, Madrid), Pablo Rojo Conejo (Hospital Universitario Doce de Octubre, Madrid), Maribel González Tomé (Hospital Universitario Doce de Octubre, Madrid), Carlos Grasa Lozano (Hospital Universitario Doce de Octubre, Madrid), Belén Toral (Hospital Universitario Doce de Octubre, Madrid), Leticia Albert De la Torre (Hospital Universitario Doce de Octubre, Madrid), Jaime de Inocencio (Hospital Universitario Doce de Octubre, Madrid), Mar Santos (Hospital Universitario Gregorio Marañón, Madrid), Rafael Díaz-Delgado de la Peña (Hospital Severo Ochoa, Leganés), Paz Collado Ramos (Hospital Severo Ochoa, Leganés), Alfredo Tagarro (Hospital Universitario Infanta Sofía, Madrid), Teresa Raga (Hospital Universitario Infanta Sofía, Madrid), Libertad Latorre (Hospital Universitario Infanta Sofía, Madrid), Sara Guillén
Kawasaki disease features in Spain (2011-2016) and risk factors for aneurysm development
Beatriz Mercader Rodríguez (Hospital Clínico Universitario Virgen de la Arrixaca, Murcia), Matilde Bustillo Alonso (Hospital Universitario Miguel Servet, Zaragoza).

Author Contributions
Conceptualization: Elisa Fernandez-Cooke, Ana Barrios Tascón, Cristina Calvo.
Formal analysis: Sara Domínguez-Rodríguez, Cristina Calvo.
Funding acquisition: Cristina Calvo.
Investigation: Elisa Fernandez-Cooke, Ana Barrios Tascón.
Methodology: Cristina Calvo.
Project administration: Elisa Fernandez-Cooke.
Software: Sara Domínguez-Rodríguez.
Supervision: Elisa Fernandez-Cooke.
Writing – original draft: Elisa Fernandez-Cooke, Cristina Calvo.
Writing – review & editing: Elisa Fernandez-Cooke, Ana Barrios Tascón, Judith Sánchez-Manubens, Jordi Antón, Carlos Daniel Grasa Lozano, Javier Aracil Santos, Enrique Villalobos Pinto, Daniel Clemente Garulo, Beatriz Mercader Rodríguez, Matilde Bustillo Alonso, Esmeralda Nuñez Cuadros, Maria Luisa Navarro Gómez, Sara Domínguez-Rodríguez, Cristina Calvo.

References
1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease. A Scientific Statement from the American Heart Association. Circulation. 2017; 135(17):e927–999. https://doi.org/10.1161/CIR.0000000000000484 PMID: 28356445
2. Burns J, Capparelli E, Brown J, Newburger J, Glode M. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998; 17(12):1144–8. PMID: 9877364
3. Dietz SM, Stijn D Van, Burgner D, Levin M, Kuipers IM, Hutten BA. Dissecting Kawasaki disease: a state-of-the-art review. Eur J Pediatr. European Journal of Pediatrics; 2017; 166(8):995–1009.
4. Kwon H, Lee JH, Jung JY, Kwak YH, Kim DK, Jung JH, et al. N-terminal pro-brain natriuretic peptide can be an adjunctive diagnostic marker of hyper-acute phase of Kawasaki disease. Eur J Pediatr. 2016; 175(12):1997–2003. https://doi.org/10.1007/s00431-016-2798-3 PMID: 27798729
5. Khor CC, Davila S, Shimizu C, Sheng S, Matsumura T, Suzuki Y, et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J Med Genet. 2011; 48(7):467–72. https://doi.org/10.1136/jmg.2010.086611 PMID: 21571869
6. Onouchi Y, Ozaki K, Buns JC, Shimizu C, Hamada H, Honda T, et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum. Mol. Genet. 2010 Jul; 19(14):2898–906. https://doi.org/10.1093/hmg/ddq176 PMID: 20423928
7. Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012; 44(5):517–21. https://doi.org/10.1038/ng.2220 PMID: 2244962
8. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008; 40(1):35–42. https://doi.org/10.1038/ng.2209 PMID: 18084290
9. Wright VJ, Herberg JA, Kafourou M, Shimizu C, Eleftherhorinou H, Shahies H, et al. Diagnosis of Kawasaki Disease Using a Minimal Whole-Blood Gene Expression Signature. JAMA Pediatr. 2018; 172(10):e182293. https://doi.org/10.1001/jamapediatrics.2018.2293 PMID: 30063721
10. Makino N, Nakamura Y, Yashiro M, Sano T, Ae R, Kosami K, et al. Epidemiological observations of Kawasaki disease in Japan, 2013–2014. Pediatr Int. 2018; 60(6):581–7. https://doi.org/10.1111/ped.13544 PMID: 29498791
11. Fischer TK, Holman RC, Yorita K, Belay ED, Melbye M, Koch A. Kawasaki syndrome in Denmark. Pediatr Infect Dis J. 2007; 26(5):411–5. https://doi.org/10.1097/01.inf.0000259964.47941.00 PMID: 17468651

12. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012; 22(2):79–85. https://doi.org/10.2188/jea.JE20110131 PMID: 22307434

13. Sánchez-Manubens J, Antón J, Bou R, Iglesias E, Calzada-Hernandez J. Incidence, epidemiology and clinical features of Kawasaki disease in Catalonia, Spain. Clin Exp Rheumatol. 2016; 34(5):S139–44. PMID: 26939753

14. Riancho-Zarate I, Rasilla D, Royo D, Fdez-Aroyabe P, Santurtún A. Kawasaki disease in Spanish paediatric population and synoptic weather types: an observational study. Rheumatol Int. 2018; 38(7):1259–66. https://doi.org/10.1007/s00296-018-4066-5 PMID: 29846788

15. Chang A, Delmerico AM, Hicar MD. Spatio-temporal analysis and epidemiology of Kawasaki disease in Western New York: A Sixteen Year Review of Cases Presenting to a Single Tertiary Care Center. Pediatr Infect Dis J. 2018; [Epub ahead of print].

16. Harris PA, Robert T, Robert T, Jonathon P, Nathaniel G, Jose C. A metadata-driven methodology and workflow process for providing translational research informatics support. Research electronic data capture (REDCap). J Biomed Inf. 2009; 42(2):377–81.

17. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006; 149:237–240. https://doi.org/10.1016/j.jpeds.2006.03.050 PMID: 16887442

18. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007; 166(2):131–7. https://doi.org/10.1007/s00431-006-0223-z PMID: 16896641

19. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006; 113:2606–12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865 PMID: 16735679

20. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114(6):1708–33. https://doi.org/10.1542/peds.2004-2182 PMID: 15574639

21. Thiele C. Cutpointr: Determine and Evaluate Optimal Cutpoints in Binary Classification Tasks. R package version 0.7.3. [Internet]. 2018. Available from: https://cran.r-project.org/package=cutpointr

22. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet]. Available from: https://www.r-project.org/

23. Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, et al. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child. 2015; 100(4):366–8. https://doi.org/10.1136/archdischild-2014-307397 PMID: 25670405

24. Eleftheriou D, Levin M, Shingadia D, Tulloch R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child. 2014; 99(1):74–83. https://doi.org/10.1136/archdischild-2012-302841 PMID: 24162006

25. Chen JJ, Ma XJ, Liu F, Yan WL, Huang MR, Huang M, et al. Epidemiological Features of Kawasaki Disease in Shanghai from 2008 Through 2012. Pediatr Infect Dis J. 2016; 35(5):7–12. https://doi.org/10.1097/INF.0000000000000914 PMID: 26372452

26. Tacke CE, Breunis WB, Pereira RR, Breur JM, Kuipers IM, Kuipers TW. Five years of Kawasaki disease in the Netherlands: a national surveillance study. Pediatr Infect Dis J. 2014; 33(8):793–7. https://doi.org/10.1097/INF.0000000000002271 PMID: 24463809

27. Burns JC, Cayan DR, Tong G, Bainto EV, Turner CL, Shike H, et al. Seasonality and temporal clustering of Kawasaki disease. Epidemiology. 2005; 16(2):220–5. PMID: 15703537

28. Cimaz R, Fanti E, Mauro A, Voller F, Rusconi F. Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records. Eur J Pediatr. 2017; 176(8):1061–5. https://doi.org/10.1007/s00431-017-2947-3 PMID: 28612175

29. Son MBF, Newburger JW. Kawasaki Disease. Pediatr Rev. 2018; 39(2):78–90. https://doi.org/10.1542/pir.2016-0182 PMID: 29437127

30. Huang YH, Kuo HC. Anemia in Kawasaki disease: Hepcidin as a potential biomarker. Int J Mol Sci. 2017; 18(4).
32. Kim GB, Park S, Eun LY, Han JW, Lee SY, Yoon KL, et al. Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012–2014. Pediatr Infect Dis J. 2017; 36(5):482–5. https://doi.org/10.1097/INF.0000000000001474 PMID: 27997519

33. Belay ED, Maddox R a, Holman RC, Curns AT, Ballah K, Schonberger LB. Kawasaki Syndrome and Risk Factors for Coronary Artery Abnormalities. Pediatr. Infect. Dis. J. 2006; 25(3):245–9. https://doi.org/10.1097/01.inf.0000202068.30956.16 PMID: 16511388

34. Tulloh RMR, Mayon-White R, Hamden A, Ramanan A V, Tizard EJ, Shingadia D, et al. Kawasaki disease: A prospective population survey in the UK and Ireland from 2013 to 2015. Arch Dis Child. 2018; [Epub ahead of print].

35. Pinto FF, Laranjo S, Carmo MM, Brito MJ, Ferreira RC. Twelve Years of Kawasaki Disease in Portugal. Pediatr. Infect. Dis. J. 2016; 36(4):1.

36. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomura K, Hayashidera T, et al. Highdose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984; 2:1055–1058. PMID: 6209513

37. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): A randomised, open-label, blinded-endpoints trial. Lancet. 2012; 379(9826):1613–20. https://doi.org/10.1016/S0140-6736(11)61930-2 PMID: 22405251

38. Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017; 1:CD011188. https://doi.org/10.1002/14651858.CD011188.pub2 PMID: 28129459

39. Phuong LK, Singh-Grewal D, Burgner DP. Caution in Generalizing the Use of Adjunctive Primary Corticosteroids in Kawasaki Disease to Unselected Non-Japanese Populations. JAMA Pediatr. 2017; 171(4):397–8. https://doi.org/10.1001/jamapediatrics.2016.5140 PMID: 28241243